Article Versions Notes

Rosman Z, Maor Y, Zohar I, Balmor GR, Pravda MS, Goldstein AL, Tocut M, Soroksky A. Proprotein Convertase Subtilisin Kexin 9 Inhibitor in Severe Sepsis and Septic Shock Patients in a Phase II Prospective Cohort Study—Preliminary Results. Infectious Disease Reports. 2024; 16(6):1036-1044. https://doi.org/10.3390/idr16060083

Rosman, Ziv, Yasmin Maor, Iris Zohar, Gingy Ronen Balmor, Miri Schamroth Pravda, Adam Lee Goldstein, Milena Tocut, and Arie Soroksky. 2024. "Proprotein Convertase Subtilisin Kexin 9 Inhibitor in Severe Sepsis and Septic Shock Patients in a Phase II Prospective Cohort Study—Preliminary Results" Infectious Disease Reports 16, no. 6: 1036-1044. https://doi.org/10.3390/idr16060083

Rosman, Z., Maor, Y., Zohar, I., Balmor, G. R., Pravda, M. S., Goldstein, A. L., Tocut, M., & Soroksky, A. (2024). Proprotein Convertase Subtilisin Kexin 9 Inhibitor in Severe Sepsis and Septic Shock Patients in a Phase II Prospective Cohort Study—Preliminary Results. Infectious Disease Reports, 16(6), 1036-1044. https://doi.org/10.3390/idr16060083